Correlation between Bronchodilator Responsiveness and Quality of Life in Chronic Obstructive Pulmonary Disease

この論文にアクセスする

この論文をさがす

著者

    • OMATA Masatoshi
    • Department of Pulmonary Medicine, Infection and Oncology, Respiratory Care Clinic, Nippon Medical School
    • WAKABAYASHI Ritsuko
    • Department of Pulmonary Medicine, Infection and Oncology, Respiratory Care Clinic, Nippon Medical School
    • KUDOH Shoji
    • Department of Pulmonary Medicine, Infection and Oncology, Respiratory Care Clinic, Nippon Medical School
    • KIDA Kozui
    • Department of Pulmonary Medicine, Infection and Oncology, Respiratory Care Clinic, Nippon Medical School

抄録

<b>Background:</b> Guidelines and literature debate the importance of testing for bronchial reversibility and its total significance is unclear. Clinically, patients with greater reversibility have higher fluctuations in respiratory symptoms, and hence may have a reduced health-related quality of life (HRQoL). On the other hand, they may have a better HRQoL as medications may be more effective in this population. Presently, there are no reports concerning the relationship between HRQoL as an indicator of therapy and reversibility. We hypothesized that the reversibility of airflow limitation might be correlated with the HRQoL in COPD.<br> <b>Methods:</b> We examined 63 subjects with COPD (mean age: 71.7 years). Reversibility was measured by the change in FEV<sub>1</sub> and FVC after the inhalation of salbutamol (300μg), and we investigated the relationship between the reversibility and the parameters of HRQoL, which included St. George's Respiratory Questionnaire (SGRQ), Visual analogue scale-8 (VAS-8), Short-Form 36-Item Health Study, Basic activities of daily living, Instrumental activities of daily living, and the Oxygen cost diagram.<br> <b>Results:</b> Post-bronchodilator FEV<sub>1</sub>, % predicted was positively correlated with both the total scores of SGRQ and VAS-8 (<i>p</i> < 0.0001 and <i>p</i> < 0.006, respectively). Furthermore, the reversibility of FVC was positively correlated with all items of the SGRQ, except for impact (total score: <i>p</i> < 0.02; symptoms: <i>p</i> < 0.02; activity, <i>p</i> < 0.05; total score of VAS-8: <i>p</i> < 0.02). However, the reversibility of FEV<sub>1</sub> was neither correlated with the total score nor any items in the scales.<br> <b>Conclusions:</b> Those who have FVC that respond to bronchodilator at rest might result in an improvement of HRQoL after treatment.<br>

収録刊行物

  • Allergology international : official journal of the Japanese Society of Allergology  

    Allergology international : official journal of the Japanese Society of Allergology 56(1), 15-22, 2007-03-01 

    Japanese Society of Allergology

参考文献:  43件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

ページトップへ